


BMJ Open Carbon footprint of healthcare systems: a systematic review of evidence and methods

Mattis Keil ,^{1,2} Leonie Frehse,³ Marco Hagemeister,³ Mona Knieß,³ Oliver Lange,^{1,4} Tobias Kronenberg,⁵ Wolf Rogowski¹

To cite: Keil M, Frehse L, Hagemeister M, *et al.* Carbon footprint of healthcare systems: a systematic review of evidence and methods. *BMJ Open* 2024;**14**:e078464. doi:10.1136/bmjopen-2023-078464

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2023-078464>).

Received 02 August 2023
Accepted 15 April 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Health Care Management, Institute of Public Health and Nursing Research, Health Sciences, University of Bremen, Bremen, Germany

²Joint research cluster “Healthy City Bremen” of the University of Bremen, Bremen University of Applied Sciences and Apollon University of Applied Sciences Bremen, Bremen, Germany

³Professional Public Decision Making, Faculty of Cultural Studies, University of Bremen, Bremen, Germany

⁴Leibniz ScienceCampus Digital Public Health, Bremen, Germany

⁵Department of Economics, Bochum University of Applied Sciences, Bochum, Germany

Correspondence to

Mattis Keil;
m.keil@uni-bremen.de

ABSTRACT

Objective Given the demand for net-zero healthcare, the carbon footprint (CF) of healthcare systems has attracted increasing interest in research in recent years. This systematic review investigates the results and methodological transparency of CF calculations of healthcare systems. The methodological emphasis lies specifically on input–output based calculations.

Design Systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline.

Data sources PubMed, Web of Science, EconBiz, Scopus and Google Scholar were initially searched on 25 November 2019. Search updates in PubMed and Web of Science were considered until December 2023. The search was complemented by reference tracking within all the included studies.

Eligibility criteria We included original studies that calculated and reported the CF of one or more healthcare systems. Studies were excluded if the specific systems were not named or no information on the calculation method was provided.

Data extraction and synthesis Within the initial search, two independent reviewers searched, screened and extracted information from the included studies. A checklist was developed to extract information on results and methodology and assess the included studies' transparency.

Results 15 studies were included. The mean ratio of healthcare system emissions to total national emissions was 4.9% (minimum 1.5%; maximum 9.8%), and CFs were growing in most countries. Hospital care led to the largest relative share of the total CF. At least 71% of the methodological items were reported by each study.

Conclusions The results of this review show that healthcare systems contribute substantially to national carbon emissions, and hospitals are one of the main contributors in this regard. They also show that mitigation measures can help reduce emissions over time. The checklist developed here can serve as a reference point to help make methodological decisions in future research reports as well as report homogeneous results.

INTRODUCTION

Background

Climate change is one of the most pressing issues of our time.¹ Considering the

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ The assessment of methodological choices and the transparency of methods when assessing the greenhouse gas (GHG) emissions of entire sectors in systematic reviews can help deepen our understanding of the results.
- ⇒ The systematic review of all available evidence on GHG emissions of and within healthcare can help to understand its impact and to identify reduction potentials.
- ⇒ This review was limited to articles in English and German, and excluded assessments, grey literature from public reports, and reports from statistical offices published in other languages.

correlation between the gross domestic product and carbon emissions,² the healthcare industry is likely an essential contributor to greenhouse gas (GHG) emissions. Demographic shifts and income effects have likely spurred greater demand for healthcare services, a trend projected to persist and further elevate the economic significance of the healthcare industry.³ Evidence on healthcare's GHG emissions is needed to understand its role better.

Methods for calculating a carbon footprint (CF) can be broadly categorised into bottom-up and top-down approaches. Bottom-up methods, such as process-based lifecycle assessments, require extensive data, which currently limits their application at a sectoral level. However, the CF of various sectors can be estimated using a more uncertain top-down methodology, providing a trade-off for broader coverage. In this case, emissions are divided according to the final demand or economic sectors of emission occurrence.

Input–output (I–O) analysis, which follows this approach, can be used to estimate sectoral CF.⁴ Calculations of the CF use the static open-quantity I–O model in combination with an environmental extension.

They rely on two fundamental building blocks: an I–O table and a demand vector. The I–O table describes the interactions between the sectors of production, often in monetary terms, and are usually constructed by national statistics offices. With additional information on their environmental impact, the emission intensity of a sector and its upstream production processes can be calculated. The demand vector represents the expenditures of the relevant sectors. For example, the demand vector of the healthcare sector includes expenditure on diesel fuel to power ambulances, electricity consumed by hospitals, and all other forms of energy. It may be necessary to synchronise the structures of the I–O table and the demand vector by balancing the definitions of different sectors and adjusting the level of sectoral aggregation.

I–O models can be grouped into single-region I–O (SRIO) and multi-region I–O (MRIO) models. SRIO models use I–O data from a single country, thus restricting their scope to domestic production and emissions only. MRIO models connect multiple I–O tables from multiple countries, and can thus account for different levels of production and ‘trade’ in emissions (ie, emissions occurring in one country related to the final demand of another country). The need for synchronised data from multiple countries complicates the development and update of the data of MRIO models.

The results of CF calculations for a specific sector can be influenced by methodological choices, including the selection between SRIO or MRIO models and the GHGs taken into account. Therefore, comprehensive reporting is needed to ensure the transparency of methodological choices, the data and the results. However, our search of the literature yielded neither a standardised procedure nor standardised reporting.

Objective

The aim of this study is to conduct a systematic review of research using I–O analysis to quantify the CF of systems, encompassing total CF, CF per capita, and its proportion relative to the national CF. Furthermore, data on emission trends over time, can deepen the understanding of the trajectory of the CF of healthcare systems. Finally, an assessment of the methodological choices and their transparency within the reviewed studies can help to discuss the state of the methodology and provides a foundation to discuss methodological differences between the studies.

METHODS

Search strategy and selection criteria

This systematic review was performed by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines⁵ (the checklist is provided in online supplemental file 1). The databases PubMed, Web of Science, EconBiz, Scopus and Google Scholar were searched for studies on 25 November 2019. The full search strategy is provided in online supplemental file 2. The search was complemented by reference tracking

within all the included studies. The updated search considered hits in PubMed and Web of Science up to December 2023.

Following the screening of the titles and abstracts, studies were included for further investigation if they had (1) addressed the method of CF calculation, (2) addressed one or more healthcare systems or subsystems and (3) been written in English or German. A healthcare system was defined as the national healthcare system, federal system and/or state system. Single entities, such as individual hospitals, and specialised branches, such as dentistry, were excluded. In addition to the criteria used for screening the titles and abstracts of articles, full-text articles were excluded if they (1) did not name the specific healthcare (sub)system, (2) did not calculate the CF or (3) did not provide any information on the method of calculation used. In the initial search, two of the authors separately screened titles and abstracts, read the full text, extracted data and assessed the transparency. In the case of disagreement, decisions were made through discussion until a consensus was reached. During the search update these steps were conducted by one person.

Data extraction and analysis

The CF per capita, the contribution of healthcare to the country’s total CF emissions, and the origins of emissions were used as main results of the studies. The breakdown of the emission sources could be in scopes, demand categories or places of origin. The Greenhouse Gas Protocol Corporate Accounting and Reporting Standard⁶ proposes three standardised scopes. Scope 1 represents direct emissions from owned or controlled sources, scope 2 represents indirect emissions generated by the purchased energy and scope 3 represents all indirect emissions that occur in the value chain. The categories of demand included the classes of expenditures of the demand vector, and the places of the origin of emissions were divided into hospitals, ambulatory services and so on.

In addition to evaluating their general characteristics and results, we developed and applied a checklist to assess the methodological transparency of the studies under consideration. We opted to use the term ‘transparency’ rather than ‘quality’ to address the issue that even a flawless study could receive a low score if the authors failed to adequately report their methodology. The checklist served as both a qualitative extraction tool and a quantitative transparency tool. The qualitative extraction tool facilitated the assessment of information from each included study, with responses to each criterion collected accordingly. As a quantitative transparency tool, it was evaluated whether the criteria were adequately addressed. When information was provided, the criterion was considered fulfilled, resulting in an increase in the transparency score. All criteria were weighted equally, therefore for each ‘fulfilled’ criterion one point was added to the transparency score, with a maximum of 17 points per study.

The utilisation of I–O data can introduce uncertainties into the assessment, given that the top-down approach relies on aggregated information from industrial sectors. When heterogeneous products with varying emission intensities are grouped into one industry, aggregation errors might occur: the average emission intensity of the aggregated industry would not appropriately reflect the emissions caused by the specific product within the industry.⁷ Therefore, information on the extend of usage of I–O method (criterion 5), and the number of industry sectors (criterion 12) could help to understand the scope of this uncertainty.

The choice between MRIO and SRIO (criterion 11) can also help to understand the level of uncertainty. While MRIOs can account for differences between countries and trade between these countries, SRIO might provide a more detailed framework of the domestic economy. Finally, the specific source of the I–O tables (criterion 9) and emission data (criterion 13) can help the reader to assess the quality of the used data.

Similar to the I–O data, the level of aggregation within the demand data can impact the accuracy of the results. The number of demand or expenditure categories (criterion 8) can indicate on the level of aggregation and the source of demand data (criterion 6) could help to assess the quality of the data source. The quality of the outcomes is also influenced by the alignment between the temporal representativeness of the demand data (criterion 7) and the I–O data (criterion 10). Changes over time (eg, in technology, import and exports) can impact the results and in the best case both data sources refer to the same year. Finally, information on the matching process of demand categories and industry sectors, the publication of the concordance matrix (criterion 15), increases transparency for the reader.

The quantitative (criterion 16) and qualitative (criterion 17) assessment of uncertainty helps the readers to contextualise the results. A list of the included GHGs can indicate the scope of the study, in this case 0.5 were given, when the unit (typically CO₂ equivalents (CO₂eq)) was mentioned and another 0.5 points if all included GHGs were listed. For the final transparency checklist, the criteria on outcomes (table 1A) and on methodology (table 1B) were combined. A more detailed description of the transparency criteria are provided in online supplemental file 3.

Emissions over time

To assess trends in GHG emissions of healthcare, data from all studies that reported total emissions for more than 1 year were taken. The data were normalised to the respective starting point of the report as a base year. Therefore, GHG emissions of time period *t* were divided by the GHG emissions of the base year *t*₀ and used in a descriptive analysis.

Patient and public involvement

None.

Table 1 (A) Extracted outcomes. (B) Extracted methodological items

	Number	Criterion
A		
System description and outcomes	0*	System description
	0*	Years for which total emissions are reported
	1	Total carbon footprint
	2	Carbon footprint as a share of the total national CF
	3	CF per capita
B		
Method	5	LCA method
	6	Source of demand data (detail)
	7	Year of demand data
	8	Number of categories of demand or expenditure
	9	Data source of I–O table
	10	Year of I–O table
	11	Multi-regionality of the model
	12	Number of production sectors
	13	Source of emission data
	14	GHGs considered
	15	Concordance matrix reported
	16	Sensitivity and uncertainty analysis
	17	Discussion of limitations
*Not included in the transparency score. CF, carbon footprint; GHG, greenhouse gas; I–O, input–output; LCA, lifecycle assessments.		

RESULTS

A total of 4285 records were identified in the three searches (figure 1). After removing duplicates and searching for eligible title, abstracts and full texts, 15 reports were included in this review (figure 1). A summary of included studies is provided in table 2. The detailed results of the data collection are listed in online supplemental files 4 and 5.

Characteristics of the studies considered

Eleven studies focused on a single national healthcare system, including England,^{8,9} Japan,¹⁰ USA,^{11,12} Canada,¹³ Scotland,¹⁴ China,¹⁵ Australia,¹⁶ Austria¹⁷ and the Netherlands.¹⁸ The series of CFs from the Sustainable Development Unit of the English NHS was aggregated, and only the newest available report was cited. One study examined the healthcare system of the largest Australian state, New South Wales,¹⁹ while three studies reported on healthcare systems in multiple countries. Pichler *et al*²⁰ reported results for 36 countries, Healthcare without Harm for 43 countries,²¹ and the investigation by Lenzen *et al*²² considered 189 countries.




Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram, based on Page *et al.*⁵

Excluding the one that assessed the Scottish NHS, all studies were published after 2016. However, it is worth noting that the year of the analysis could be older. For instance, the study by Nansai *et al.*¹⁰ was published in 2020 but used demand data from 2011.

Differences in methodology and data

Eleven studies considered top-down data on emissions, while three studies employed bottom-up data on energy usage.^{8 9 14} Steenmeijer *et al.*¹⁸ incorporated bottom-up data regarding the quantities of anaesthetic gases, inhalers and travel.

Most single-country studies used SRIOD data from the respective governmental offices. In contrast, the studies on British and Dutch healthcare, and those that considered more than one country, used MRIO data. Additionally, Malik *et al.*²³ used MRIO data, however, the database only included data from Australian regions. The EORA database emerged as the most frequently used MRIO

database (three times), with one study each employing the WIOD database, the EXIOBASE database and the MRIO database provided by the British Department for the Environment, Food, and Rural Affairs.

The number of production sectors varied among the SRIOD studies, ranging from 46 to 405 sectors. The MRIO studies typically used more extensive databases comprising approximately 15 000 sectors, although the MRIO study focusing on the UK considered 424 sectors.

All studies considered CO₂ emissions. However, only five studies considered the six GHGs covered in the Kyoto Protocol; three studies considered CO₂, methane and nitrous oxide; two reported only that they had used CO₂eq as unit; and two studies did not report any included GHG or the unit in which the outcomes were reported. The data on emissions were drawn mostly from national accounts in the case of SRIOD databases and integrated accounts in the case of MRIO databases.

Table 2 Characteristics and main results of the studies considered in this review

Author	Healthcare system	Years total emissions reported	Latest year of emissions reported	CF in Mt CO ₂ eq	% of total national CF	tCO ₂ eq/cap	Transparency score (%)
Tennison <i>et al</i> ⁸	England	1990–2019	2019	25	n.i.	0.445	88
SDU ⁹	England	1992–2017	2017	25	n.i.	n.i.	71
Nansai <i>et al</i> ¹⁰	Japan	2011–2015	2015	72	4.6	0.49	82
Eckelman and Sherman ¹¹	USA	2003–2013	2013	655	9.8	2.07	85
Eckelman <i>et al</i> ¹²	USA	2010–2018	2018	554	n.i.	n.i.	76
Eckelman <i>et al</i> ¹³	Canada	2009–2015	2015	33	5.7	0.92	94
Health Facilities Scotland ¹⁴	Scotland	1990–2004	2004	2.6	3.6	0.52	76
Wu ¹⁵	China	2012	2012	315	2.,7	0.23	94
Malik <i>et al</i> ¹⁶	Australia	2013–2015	2015	36	7.0	1.50	85
Weisz <i>et al</i> ¹⁷	Austria	2014	2014	6.8	7	0.8	94
Steenmeijer <i>et al</i> ¹⁸	Netherlands	2016	2016	17 575	17.6	n.i.	88
Malik <i>et al</i> ¹⁹	New South Wales, Australia	2017	2017	0.008	6.6	n.i.	71
Pichler <i>et al</i> ²⁰	OECD countries; China, India	2014	2014	Online supplemental file 4	Ø 5.5 s. Online supplemental file 4	Online supplemental file 4	94
Karlner <i>et al</i> ²¹	43 countries; EU; rest of the world	2014	2014	Online supplemental file 4	Ø 4.4 s. Online supplemental file 4	Online supplemental file 4	88
Lenzen <i>et al</i> ²²	Global	2007–2015	2015	2290	n.i.	n.i.	88

cap, capita; CF, carbon footprint; CO₂eq, CO₂ equivalents; EU, European Union; Mt, megatonnes; n.i., not identified; OECD, Organisation for Economic Co-operation and Development; t, tonnes.

One study did not report the source of its emission account data.

The demand data was taken either from official health expenditure accounts or from international organisations such as the WHO and the World Bank (which uses data provided by national offices and accounts). Lenzen *et al*²² identified and directly used data on healthcare-related sectors from the MRIO database EORA. The number of reported expenditure accounts varied, mostly ranging from 13 to 19, although three studies reported fewer accounts. Weisz *et al*¹⁷ used nine accounts, Wu¹⁵ used eight accounts, and the study on the NHS in England employed five accounts.⁹ Due to the distinct methodologies employed by Lenzen *et al*²² and the structure of the EORA database, which reports country-specific sectors, they used 163 sectors from the EORA as demand data.

The time periods covered by the demand data were largely consistent with those covered by the respective I–O data. Some studies reporting outcomes for more than 1 year only used one reference year for the I–O database and adjusted the demand data for inflation.^{11–13} The lag between the time at which the data were collected and the time of publication of the corresponding study ranged from 3 to 6 years, with deviations in the studies by Nansai *et al*,¹⁰ Eckelman *et al*¹² (2 years) and in the report by the SDU.⁹ The latter reported the CF periodically; the lag between the latest publication and the latest data was 1 year.⁹ Further information on this is provided in online supplemental file 5.

Five studies provided their concordance matrices, which link the categories of demand with the industrial sectors. The authors of one study had made their matrix available on request, and two articles had referred to a matrix previously used in another study. Five studies did not report their concordance matrices.

Reporting of the results

The origins of emissions were documented six times in the three scopes defined by the GHG protocol. Emission sources were reported eight times in the (sub)categories of final demand, such as hospitals or pharmaceuticals. Two studies reported the economic sector in which the emissions occurred, for example, the textile sector or the manufacture of fuels. Furthermore, three studies reported a breakdown of emissions by employing more than one reporting structure. Several differences were observed in the scopes of the reported results. Some studies directly referenced the GHG protocol while others reported emissions in divisions, such as travel, energy, procurement, etc. 47% of the articles did not normalise the results by reporting the CF per capita.

Overall transparency

Except for the three criteria ‘reporting of the concordance matrix’, ‘uncertainty analysis’ and ‘CF per capita’, all criteria were fulfilled by at least 75% of the studies (figure 2). The studies fulfilled between 70.5% and 94% of all criteria with a mean of 85% (figure 3). The full transparency assessment is provided in online supplemental file 6.

OUTCOMES

Emissions over time

The results of the time series revealed successful efforts to mitigate the CF by the NHS in England and Scotland (figure 4). In the nearly three decades from 1990 to 2019, the English NHS reduced its CF by roughly 25%. The four remaining countries (Japan, Canada, USA and Australia) examined in the studies considered here and the global trend showed increased CF due to healthcare (figure 4). The annual increase in the CF ranged from 0.7% (USA, 2010–2018) to 3.8% (Japan, 2011–2015) over the observed




Figure 2 Fulfilment rate of the transparency and reporting criteria.




Figure 3 Transparency score in percentage per article.

period, with the CFs of Canada (1.9%, 2009–2015), USA (2.8%, 2011–2015) and Australia (2.9%, 2013–2015) in between these extremes. The global trend showed an increase in the CF of 2.7% per year from 2000 to 2015.

Breakdown

The emission sources were mainly reported using the scope system from the GHG protocol or the categories of expenditure, that is, the categories of final demand. The largest dataset that used the categories of final demand was provided by Pichler *et al.*²⁰ who applied this to 36 countries and reported the average values. Medical retail (ie, provider of healthcare products without medical services, eg, pharmacies), hospitals and ambulatory healthcare services constituted 80% of the CF of healthcare, with medical retail contributing 33.1%, hospitals 28.6% and ambulatory healthcare services 18%. They also made a major contribution to the CF in Japan (hospitals, 25.1%; ambulatory services, 22.7%), USA in 2013 (hospital care, 36%; physician and clinical services, 12%)¹¹ and in 2018

(hospital care, 34.9%; physician and clinical services, 12.6%; ambulatory medical services, 4.8%),¹³ Australia (public hospitals, 34.4%; private hospitals, 10.2%; ambulatory medical services, 15%),¹⁶ China (public hospitals, 47%; private hospitals, 4%)¹⁵ and Austria (hospitals, 32%; ambulatory services, 18%).¹⁷ Other important categories of emissions were construction and pharmaceutical products, at around 10%,^{11 16 20} with a higher share in China (pharmaceuticals, 18%; construction, 15%).¹⁵

An alternative approach involved categorising emissions into direct emissions, indirect emissions through electricity production, and other indirect emissions. This division along these lines could also align with the three GHG protocol scopes.

By averaging data from 43 countries, HCWH reported a distribution of 17% for scope 1 emissions, 12% for scope 2 emissions and 71% for scope 3 emissions.²¹ These findings, particularly the significance of scope 3 emissions, are corroborated by evidence from single-country studies.^{8 11 12 14 24} The scope 3 emissions were further divided into those due to travel (patient and visitor travel, and staff commutes), production of pharmaceuticals, and medical instruments and equipment, which accounted for the largest share of scope 3 emissions.

Scotland's scope 3 travel emissions in 2004 were 18% while those of England accounted for 13% in 2015 and 9.6% in 2018.⁹ The share of emissions owing to pharmaceutical production ranged from 11% to 18%, and that owing to medical instruments and equipment accounted for 7%–10% of the total CF.^{13 14 24}

The ratio of emissions by the healthcare sector to the total CF in studies focused on a single country ranged from 2.7% in China in 2012¹⁵ to 9.8% in the USA in 2013.¹¹ The three cross-national studies considered here estimated that healthcare had contributed 5.5%²⁰ on average to the national CF in 2014 and 4.4% in 2015.²²




Figure 4 Emission trends over time. CF, carbon footprint.

DISCUSSION

Interpretation of results

The results indicate that healthcare significantly contributes to the CF, both in absolute numbers and in relation to a country's overall emissions and its per capita emissions. However, the results varied among the studies, and their calculation methods were heterogeneous and frequently not fully transparent. The breakdown of the sources of emissions revealed the major contribution made by hospitals.

The time series results showed that the trend of emissions due to healthcare was positive in all the countries considered, that is, they were increasing, except in Scotland and England. These results align with the graphical results provided by Lenzen *et al.*²² Furthermore, they indicated that the efforts of the British NHS systems to reduce their CF based on the Greener NHS programme was effective in reducing GHG emissions. The breakdown of the sources of emissions verified the important contribution of hospitals. However, hospitals provide the majority of medical care in many countries. Therefore, their large CF is not surprising but might motivate the relevant decision-makers to allocate scarce resources more efficiently. The breakdown further showed that a large portion of the CF of healthcare stemmed from scope 3 emissions. Decision-makers may conclude that the most considerable reduction in emissions can be obtained by considering staff and patient travel. Therefore, 'greening' the healthcare sector requires a sustainable transportation system and green healthcare goods.

Most data were from the Organisation for Economic Co-operation and Development (OECD) countries, China and India. The only exception was the work by Lenzen *et al.*²² who considered 189 countries in their analysis.²² However, even if the distribution of countries limits the representativeness of the results, the findings are consistent with the fact that OECD countries are the main emitters of GHGs.

While heterogeneity in methodology, in general, can lead to more robust results and a more informative perspective on the issue at hand, the differences in I–O methodologies to calculate the CF of healthcare may reduce the comparability of the results. However, the choice of method depends on the corresponding research question, for example, while SRIO may be more up-to date and include a more detailed description of the domestic production sectors, MRIO can account for international trade and differences in production emissions between countries.

Limitations

This review has several limitations. First, the review process used here was limited due to restrictions on the language used in the study and those related to access. Second, it is possible that further CF assessments exist which were published in the official languages of many countries in the grey literature, such as publications by national statistics offices or governmental agencies. Because this review

included only publications in English and German, many such studies have likely been neglected. Third, the reporting scheme and transparency score used in this study may have limitations. Both were based only on a consensus among the authors. The instruments used to assess the quality of the published studies are typically chosen based on a broad consensus among experts, such as in the case of the Consolidated Health Economic Evaluation Reporting Standards.²⁵ However, we did not find similar guidance for I–O analyses. Finally, the review is limited as the studies only report averages instead of CIs or data ranges. Only Malik *et al.*¹⁶ report the 68% CI with a range of 20 748 kt CO₂eq in the results (68% CI 25 398 kt CO₂eq to 46 146 kt CO₂eq). Therefore, the results presented in both the individual studies and in this review should not be regarded as precise measurements, but rather as indicative trends or directions.

Implications for further research

This review identified research gaps that should be investigated by future research. First, there is a need to assess the potential effects of efforts to reduce emissions on the system and pathways to a low-carbon healthcare system. Second, it should be examined errors of aggregation when using the I–O methodology in the healthcare context. Third, the differences in the outcomes when making different methodological choices (SRIO or MRIO, systemic boundaries, etc) should be analysed to guide future research.

The transparency checklist used in this study can serve as an initial reference point for future developments. For example, in the checklist's current state, all criteria are weighted equally. However, some might be less crucial to delivering harmonised study findings. An extended consensus process with further experts is proposed to validate the checklist further and increase its value for research and practice.

X Mattis Keil @MattisKeil

Acknowledgements We would like to thank Frauke Waßmuth for her help in the screening and extracting phase of the search update.

Contributors MKeil (guarantor): methodology, screening, formal analysis, writing – original draft, writing – review and editing, visualisation; LF, MH, MKnieß: methodology, screening, formal analysis, writing – original draft; OL: conceptualisation, methodology, writing – review and editing; TK: methodology, writing – review and editing. WR: conceptualising, methodology, writing – review and editing, supervision, project administration. All authors have read and approved the final manuscript for publication.

Funding This work was supported by the Leibniz ScienceCampus Bremen Digital Public Health (lsc-diph.de), which is jointly funded by the Leibniz Association (W4/2018), the Federal State of Bremen, and the Leibniz Institute for Prevention Research and Epidemiology (BIPS) for OL's inputs to the research project. The funder had no role in the study design, the collection, analysis, interpretation or submission of the data. MKeil's inputs were supported by the research cluster 'Health City Bremen' which is funded by the Federal State of Bremen. The funder had no role in the study design, the collection, analysis, interpretation or submission of the data.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Data are available upon reasonable request. The data that support the findings of this study are available in online supplemental file 4 'System description and results' and online supplemental file 5 'Methods and transparency'. Further data are available from the corresponding author (MKeil), upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Mattis Keil <http://orcid.org/0000-0003-0180-2358>

REFERENCES

- 1 IPCC. IPCC, 2022 summary for policymakers. In: Pörtner H-O, Roberts DC, Tignor M, eds. *Contribution of Working Group II to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change*. Cambridge University Press, 2022.
- 2 Sharma SS. Determinants of carbon dioxide emissions: empirical evidence from 69 countries. *Applied Energy* 2011;88:376–82.
- 3 Kronenberg T. The impact of demographic change on energy use and greenhouse gas emissions in Germany. *Ecological Economics* 2009;68:2637–45.
- 4 Minx JC, Wiedmann T, Wood R, et al. Input–output analysis and carbon Footprinting: an overview of applications. *Eco Syst Res* 2009;21:187–216.
- 5 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev* 2021;10:89.
- 6 WBCSD and WRI. The greenhouse gas protocol - A corporate accounting and reporting standard. 2004.
- 7 Yang Y, Heijungs R, Brandão M. Hybrid life cycle assessment (LCA) does not necessarily yield more accurate results than process-based LCA. *J Clean Product* 2017;150:237–42.
- 8 Tennison I, Roschnik S, Ashby B, et al. Health care's response to climate change: a carbon footprint assessment of the NHS in England. *Lancet Planet Health* 2021;5:e84–92.
- 9 SDU. "Delivering a 'net zero' national health service". 2020.
- 10 Nansai K, Fry J, Malik A, et al. Carbon footprint of Japanese health care services from 2011 to 2015. *Res Conserv Recy* 2020;152.
- 11 Eckelman MJ, Sherman J. Environmental impacts of the U.S. health care system and effects on public health. *PLOS ONE* 2016;11:e0157014.
- 12 Eckelman MJ, Huang K, Lagasse R, et al. Health care pollution and public health damage in the United States: an update. *Health Affairs* 2020;39:2071–9.
- 13 Eckelman MJ, Sherman JD, MacNeill AJ. Life cycle environmental emissions and health damages from the Canadian Healthcare system: an economic-environmental-Epidemiological analysis. *PLOS Med* 2018;15:e1002623.
- 14 Health Facilities Scotland. Carbon footprint of NhsScotland (1990–2004). 2008.
- 15 Wu R. The carbon footprint of the Chinese health-care system: an environmentally extended input–output and structural path analysis study. *Lancet Planet Health* 2019;3:e413–9.
- 16 Malik A, Lenzen M, McAlister S, et al. The carbon footprint of Australian health care. *Lancet Planet Health* 2018;2:e27–35.
- 17 Weisz U, Pichler P-P, Jaccard IS, et al. Carbon emission trends and Sustainability options in Austrian health care. *Res Conser Recy* 2020;160:104862.
- 18 Steenmeijer MA, Rodrigues JFD, Zijp MC, et al. The environmental impact of the Dutch health-care sector beyond climate change: an input–output analysis. *Lancet Planet Health* 2022;6:e949–57.
- 19 Malik A, Padget M, Carter S, et al. Environmental impacts of Australia's largest health system. *Resources, Conservation and Recycling* 2021;169:105556.
- 20 Pichler P-P, Jaccard IS, Weisz U, et al. International comparison of health care carbon footprints. *Environ Res Lett* 2019;14:064004.
- 21 Karliner J, Slotterback S, Boyd R, et al. Health care's climate footprint: Healthcare without harm an ARUP. 2019.
- 22 Lenzen M, Malik A, Li M, et al. The environmental footprint of health care: a global assessment. *Lancet Planet Health* 2020;4:e271–9.
- 23 Malik A, Egan M, du Plessis M, et al. Managing Sustainability using financial accounting data: the value of input-output analysis. *J Clean Product* 2021;293:9.
- 24 SDU. Carbon footprint update for NHS in England 2015. 2016.
- 25 Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *Int J Technol Assess Health Care* 2022;38:e13.



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Title, Methods
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Introduction on Page 3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Introduction on Page 3
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Methods section on Page 4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Methods section on Pages 3-4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplementary materials
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Methods section on Page 4
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Methods section on Page 4
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Methods section on Pages 4-5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Methods section on Pages 4-5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	n.a.
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Methods section on Page 4
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	n.a.
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	n.a.



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	n.a
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	n.a.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	n.a.
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	n.a
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	n.a.
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	n.a
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Results on page 5
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	n.a.
Study characteristics	17	Cite each included study and present its characteristics.	Results on pages 5-6
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	n.a.
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Results on pages 6-7
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	n.a.
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	n.a.
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	n.a.
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	n.a.
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	n.a.
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	n.a.
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Discussion on page 8
	23b	Discuss any limitations of the evidence included in the review.	Discussion on page 8
	23c	Discuss any limitations of the review processes used.	Discussion on page 8
	23d	Discuss implications of the results for practice, policy, and future research.	Discussion on page 9
OTHER INFORMATION			



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 9
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 9
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	n.a.
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 10
Competing interests	26	Declare any competing interests of review authors.	Page 10
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Appendix

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71
 For more information, visit: <http://www.prisma-statement.org/>

Full search strategies for all databases

DATABASE	SEARCH TERM
SCOPUS	TITLE-ABS((((footprint OR "carbon emission" OR "greenhouse gas*")) AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")))) OR ("input-output" AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")) AND ((footprint OR "carbon emission" OR "greenhouse gas*" OR environmental* extended)))) AND NOT DOCTYPE(ed) AND NOT DOCTYPE(er) AND NOT DOCTYPE(le) AND NOT DOCTYPE(no) AND NOT DOCTYPE(pr)
WEB OF SCIENCE	TOPIC: (((((footprint OR "carbon emission" OR "greenhouse gas*")) AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")))) OR ("input-output" AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")) AND ((footprint OR "carbon emission" OR "greenhouse gas*" OR environmental* extended))))Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC.
ECONBIZ	(((footprint OR "carbon emission" OR "greenhouse gas*")) AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")))) OR ("input-output" AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")) AND ((footprint OR "carbon emission" OR "greenhouse gas*" OR environmental* extended)))
PUBMED	Search (((footprint OR "carbon emission" OR "greenhouse gas*")) AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")))) OR ("input-output" AND (("health care" OR "healthcare" OR "health-care" OR "health sector" OR "health system" OR "health services")) AND ((footprint OR "carbon emission" OR "greenhouse gas*" OR environmental* extended)))

S1: Further description of the transparency criteria

#	Criteria	Further description
System description and results		
0 (not included in the transparency score)	System description	It should be reported which national healthcare system was assessed. Healthcare system was defined, closely to the definition of the WHO as follows: <i>“A health system consists of organizations, people and actions whose primary intent is to promote, restore or maintain health.”</i>
1	Total Carbon Footprint	The total CF of a healthcare system can help to understand the total impact the system has on climate change
2	Carbon Footprint as a share of the total national CF	The share of healthcare’s CF of the total national CF can help to understand the importance of the healthcare system to mitigate the climate impact of a country as well as to analyze systematic differences in the importance of the healthcare systems in mitigating the national CF between countries
3	CF per capita	The CF per capita can help to compare healthcare systems between different-sized countries.
4	CF breakdown	The division of total CFs in scopes or subcategories can help to understand the “hot spots” in GHG emissions within healthcare systems.
Method and Transparency		
5	LCA method	The LCA method can be distinguished between Top-Down (i.e. Using only Input-Output Data), Bottom-Up (i.e. using only Process-based data), and Hybrid (Using both data types). Each type has its advantages and disadvantages and should be reported to enable a first assessment of the used method.
6	Demand Date source (detail)	To avoid inaccurate, outdated, or unfitting data the data source is important to report for transparency.
7	Demand Data year	To avoid inaccurate, outdated, or unfitting data the data year is important to report for transparency.
8	Number of demand or expenditure categories	The number of demand or expenditure categories can help to assess the level of detail in which the healthcare system is modeled. The more expenditure categories are used, the higher the level of detail might be.
9	I-O table data source	Similar to the demand vector, the data source of the I-O table is important to ensure the data quality and transparency
10	I-O table year	Similar to the demand vector the data year of the I-O table is of importance to ensure the data quality and transparency
11	Multiregionality of the model	I-O tables can be distinguished in SRIO, which aggregates the economic sectors of a single country, or MRIO, which aggregates the sectors of multiple countries. As each of the models has its implications it is important to report the model type.
12	Number of production sectors	The number of production sectors within the I-O model can help to estimate the level of aggregation. The more production sectors are used the less aggregated the model might be.

13	Source of emission data	The report of emissions data sources ensures the quality.
14	Included GHGs	The results might vary dependent on the included GHGs with more included GHG leading to a higher CF. This leaves room for biases and reduced comparability between the studies. A list of the included GHGs and the used unit for the results can help to identify differences between the studies and contextualizes the results.
15	Concordance matrix reported	The bridge matrix connects the demand vector with the IO table. Each value in the demand vector, representing a demand from a certain economic sector, has to be connected to one or multiple sectors within the IO table. The bridge matrix defines these connections and makes the connection operationalizable. The bridge matrix can be either presented in matrix form or as a table classifying the demand vector values to IO table sectors.
16	Sensitivity and Uncertainty analysis	Quantitative analysis of uncertainty can add clarity and transparency to uncertainty reporting to the reader. Furthermore, it can help prioritize efforts to improve data quality in those areas of uncertainty which contribute most to the overall uncertainty of the results
17	Discussion of limitations	A variety of limitations can arise from CF calculations with IO models (e.g. insufficient data, high level of aggregation, etc.). Therefore, a critical discussion of limitations can increase transparency.

BMJ Open

Keil M, *et al.* *BMJ Open* 2024; 14:e078464. doi: 10.1136/bmjopen-2023-078464

Roosendaal et al.	2022	The environmental impact of the Dutch health care sector beyond climate change: an input-output analysis	Netherlands	17075 kg CO2eq	c.s.	7.30%	Scope 1 (Operational impacts including anaesthetic gases): 0.0%; Scope 2 (total): 11.1%; Scope 2 (Electricity): 10.5%; Scope 2 (Steam and hot water supply): 0.6%; Scope 3 (total): 78.9%; Scope 3 (Coal & peat): 0.1%; Scope 3 (Construction): 1.0%; Scope 3 (Electrical, electronic, electromechanical equipment): 7.0%; Scope 3 (Food, beverages & agricultural products): 5.8%; Scope 3 (Furniture & timber): 0.1%; Scope 3 (General and special machinery): 1%; Scope 3 (Metal products): 0.3%; Scope 3 (Metals & metal products): 0.0%; Scope 3 (Natural gas & gasoline fuels): 0.0%; Scope 3 (Non-metallic mineral products): 0.3%; Scope 3 (Paper products): 1.3%; Scope 3 (Pharmaceuticals & chemical products): 41.2%; Scope 3 (MEDICINE products): 0.0%; Scope 3 (Private travel by patients & visitors): 0.3%; Scope 3 (Services): 0.7%; Scope 3 (Travels): 0.4%; Scope 3 (Transport): 1.7%; Scope 3 (Transport equipment): 0.1%; Scope 3 (Waste management & disposal): 1.6%; Scope 3 (Water distribution): 0.2%; Scope 3 (Private travel by patients and visitors): 2%
-------------------	------	--	-------------	----------------	------	-------	--

Appendix: Method and transparency

Please use Ctrl + Scroll to zoom in this electronic appendix

Method	Demand Data source (detail)	Demand Data year	Number of demand/Expenditure categories	I-O table data source	I-O table data year	I-O model	Number of production sectors	Source of emission data/satellite account	Included Greenhouse Gases	Concordance matrix reported	Sensitivity/Uncertainty Analysis	Discussion of limitations
Top-Down	"National Medical Expenses Statistics"	2011	16	Ministry of internal Affairs and Communication	2011	SRIO (JIOT)	397	Japan National Report of GHGs Inventory (NRI)	CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ and NF ₃	No	No	Yes
Top-Down	US National Health Expenditure Accounts	2003–2013	15	Federal Bureau of Economic Analysis	2002	SRIO	400+	EIOLCA	Equivalents	Yes	No	Yes
Top-Down	OECD: OECD health statistics database; China+India: World Bank health care expenditure	2014	OECD: 19	Eora	2014	MRIO (Eora)	14839	EDGAR	CO ₂	Available upon request	No	Yes
Top-Down	National Health Expenditures (NHEX) database maintained by the Canadian Institute for Health Information (CIHI)	2009-2015	13	(Statistics Canada)	2009	SRIO (Open IO-Canada)	112 sectors, 238 commodities	Statistics Canada Environmental Accounts and the Canadian National Pollutant Release Inventory	carbon dioxide, methane, and nitrous	Yes	No	Yes
Top-Down	Australian Institute of Health and Welfare (AIHW)	2015	16	Australian Bureau of Statistics	2014-2015	SRIO (Individually constructed)	360	Sydney University IELab	Equivalents	No	Monte-Carlo	Yes
Top-Down	national input-output table, China Health and Family Planning Statistics, China Construction Statistics, and China Science and Technology Statistics yearbooks	2013	8	National Bureau of Statistics of China	2012	SRIO	46	Climate Change Department of National Development and Reform Commission of the People's Republic of China. The People's Republic of China First Biennial Update Report on Climate Change	CO ₂ , CH ₄ , and N ₂ O emissions	No	Monte-Carlo + Robustness (w/ onsite-emission in the medical institution sector) + Sensitivity (w/ energy intensities of floorspace of commercial buildings)	Yes
Hybrid	Scottish Government health expenditure	1990-2004	17	Scottish Government	1990-2004	SRIO (Scottish Government Input-Output tables)	123	UK National Statistics Environmental Accounts	CO ₂	Allocation without quantitative description	No	No
Hybrid	English Government	2004-2015	5	DEFRA	2004-2015	MRIO (UK-MRIO)	178	National Statistics Environmental Accounts	CO ₂ Beginning in 2010: CH ₄ , N ₂ O, HFCs, PFCs, SF ₆	Allocation without quantitative description	No	No
Top-Down	OECD health statistics database; World Health Organization, "Global Health Expenditure Database,"	2014	No	WIOD	2014	MRIO (WIOD)	2408	CO ₂ : WIOD; Methane and Nitrous oxide: PRIMAP	carbon dioxide, methane and nitrous oxide gases	Reference to Pichler et al. (2019)	No	Yes
Top-Down	OECD Health Statistics 2017 supplied by the Austrian national statistical office	2014	9	Eora	2014	MRIO (Eora)	15909	EORA taken from EDGAR	CO ₂	Reference to Pichler et al. (2019)	No	Yes
Top-Down	Australian Institute of Health and Welfare	2016-2017	16	Australian Bureau of Statistics (ABS)	2017	SRIO (Individually constructed)	2880	No	No	No	No	Yes
Top-Down	National Health Expenditure Accounts of the Centers for Medicare and Medicaid Services (CMS)	2010-2018	16	Bureau of Economic Analysis	2012	SRIO (US Environmentally-Extended Input-Output model)	405	Inventory of U.S. Greenhouse Gas Emissions and Sinks	No	Yes	No	Yes
Hybrid	Public Expenditure Statistical Analysis Supply and Use tables from HM Treasury	1990-2019	19	DEFRA	1997-2016	MRIO (UK-MRIO)	424	UK MRIO	carbon dioxide [CO ₂], methane [CH ₄], nitrous oxide [N ₂ O], and some categories of fluorinated gases/all Kyoto Protocol greenhouse gases	Yes	No	Yes
Top-Down	EORA	2000-2015	163	Eora	2000-2015	MRIO (Eora)	14838	EORA taken from EDGAR	carbon dioxide [CO ₂], methane, nitrous oxide, hydrofluorocarbon, chlorofluorocarb	No	Uncertainty	Yes
Hybrid	Centraal Bureau voor de Statistiek	2016	3	EXIOBASE	2016	MRIO (EXIOBASE)	7.987	EXIOBASE	CO ₂ , CH ₄ , N ₂ O	Yes	No	Yes

Appendix: Transparency Score

Please use Ctrl + Scroll to zoom in this electronic appendix

Author	Year	Author (Year)	Title	Health Care System	Total Carbon Footprint	tCO2/capita	% of total emission	Breakdown	Method	Demand Data source	Demand Data year	Number of demand/ Expenditure categories	I-O table data source	I-O table data year	Multiregionality of the model	Number of production sectors	Source of emission data/ satellite account	Included Greenhouse Gases	Concordance matrix reported	Sensitivity /Uncertainty Analysis	Discussion of limitations		
Nansai et al.	2020	Nansai et al. (2020)	Carbon footprint of Japanese health care services from 2011 to 2015	Japan	1	0	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	14	82,35%
Eckelman et al.	2016	Eckelman et al. (2016)	Environmental Impacts of the U.S. Health Care System and Effects on Public Health	USA	1	0	1	1	1	1	1	1	1	1	1	1	1	0,5	1	0	1	14,5	85,29%
Pichler et al.	2019	Pichler et al. (2019)	International comparison of health care carbon footprints	OECD countries; China; India	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	16	94,12%
Eckelman et al.	2018	Eckelman et al. (2018)	Life cycle environmental emissions and health damages from the Canadian healthcare system: An economic-environmental-epidemiological analysis	Canada	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	16	94,12%
Malik et al.	2018	Malik et al. (2018)	The carbon footprint of Australian health care	Australia	1	0	1	1	1	1	1	1	1	1	1	1	1	0,5	0	1	1	14,5	85,29%
Wu	2019	Wu (2019)	The carbon footprint of the Chinese health-care system: an environmentally extended input-output and structural path analysis study	China	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	16	94,12%
NHSScotland	2008	NHSScotland (2008)	National Health Service Scotland Carbon Footprint of NHS Scotland(1990-2004)	Scotland	1	0	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	13	76,47%
SDU series	2016	SDU series (2016)	Carbon update for the health and care sector in England 2015	NHS England	1	0	0	1	1	1	1	1	1	1	1	1	1	1	0	0	0	12	70,59%
HCH	2019	HCH (2019)	Health Care's Climate Footprint	43 countries	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	0	1	15	88,24%

Weisz et al.	2020	Weisz et al. (2020)	Carbon emission trends and sustainability options in Austrian health care	Austria	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	16	94,12%	
Malik et al.	2021	Malik et al. (2021)	Environmental impacts of Australia's largest health system	New South Wales, Australia	1	0	1	0	1	1	1	1	1	1	1	1	0	0	1	0	1	12	70,59%
Eckelman et al.	2020	Eckelman et al. (2020)	Health Care Pollution And Public Health Damage In The United States: An Update	USA	1	0	0	1	1	1	1	1	1	1	1	1	0	1	0	1	13	76,47%	
Tennison et al.	2021	Tennison et al. (2021)	Health care's response to climate change: a carbon footprint assessment of the NHS in England	England	1	1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	15	88,24%	
Lenzen et al.	2020	Lenzen et al. (2020)	The environmental footprint of health care: a global assessment	189 countries	1	1	1	0	1	1	1	1	1	1	1	1	1	0	1	1	15	88,24%	
Steenmeijer	2022	Steenmeijer et al. (2022)		Netherlands	1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	15	88,24%		
					15	7	12	13	15	15	15	14	15	15	15	15	11	12	11	3	13		
					100,00%	46,67%	80,00%	86,67%	100,00%	100,00%	100,00%	93,33%	100,00%	100,00%	100,00%	100,00%	73,33%	80,00%	73,33%	20,00%	86,67%		